重组人IL-11治疗对放化疗鼻咽癌患者预后的影响

发布时间：2019-01-03 15:02

【摘要】：目的:探讨重组人IL-11治疗对放化疗鼻咽癌患者预后的影响。方法:将78例鼻咽癌患者按随机信封抽签原则分为观察组与对照组各39例,对照组给予常规放化疗,观察组在对照组治疗的基础上给予重组人IL-11治疗,两组都完成2个周期治疗。结果:观察组总有效率(87.2%)高于对照组(59.0%),差异有统计学意义(P0.05)。观察组在治疗期间放射性口腔黏膜炎0级14例,Ⅰ级6例,Ⅱ级14例,Ⅲ级5例;对照组0级28例,Ⅰ级5例,Ⅱ级4例,Ⅲ级2例,总体比较差异有统计学意义(P0.05)。治疗后观察组与对照组的血清CRP分别为(5.32±1.92)mg/L和(12.44±2.48)mg/L,明显低于治疗前的(24.59±3.14)mg/L和(24.12±2.87)mg/L(均P0.05);治疗后,观察组血清CRP明显低于对照组(P0.05)。治疗后观察组与对照组的疼痛评分明显低于治疗前(P0.05);治疗后,观察组疼痛评分低于对照组(P0.05)。结论:重组人IL-11治疗在放化疗鼻咽癌患者中的应用能促进血清CRP表达下降,缓解疼痛,减轻放射性口腔黏膜炎,从而提高预后疗效。
[Abstract]:Objective: to investigate the effect of recombinant human IL-11 on the prognosis of patients with radiotherapy and chemotherapy nasopharyngeal carcinoma (NPC). Methods: 78 patients with nasopharyngeal carcinoma were randomly divided into two groups according to the principle of random drawing of lots in envelopes: the observation group and the control group. The control group received routine radiotherapy and chemotherapy. The observation group was treated with recombinant human IL-11 on the basis of the treatment of the control group. Two cycles of treatment were completed in both groups. Results: the total effective rate of the observation group (87.2%) was higher than that of the control group (59.0%), the difference was statistically significant (P0.05). There were 14 cases of radiation oral mucositis grade 0, 6 cases of grade 鈪，

本文编号：2399543